Loading
Loading
Research Overview
Khavinson dipeptide (Lys-Glu) with broad regulatory activity; proposed to modulate immune senescence and gene expression in thymic and immune tissue, with reported longevity effects in rodent studies.
Vilon is a short regulatory peptide that has been studied in preclinical research programs examining thymus-associated peptides and their role in immune-related cellular regulation. It has been evaluated primarily in experimental models of immune aging and immune system dysregulation, where alterations in gene expression and signaling balance are commonly observed. Vilon belongs to a group of low–molecular-weight peptides investigated for their ability to influence intracellular regulatory processes rather than acting through membrane-bound receptors or classical hormonal pathways.
Preclinical studies examining Vilon and closely related thymus peptides have reported associations with changes in gene expression profiles relevant to immune cell differentiation and immune signaling pathways. In cellular and animal models, Vilon exposure has been linked to altered transcription of genes involved in immune coordination, inflammatory signaling balance, and age-associated immune changes. These observations are reported most consistently in studies evaluating aging models or experimentally induced immune dysregulation.Mechanistic investigations suggest that Vilon does not function as a direct immune stimulant or suppressor. Instead, it has been studied for its association with regulatory modulation at the transcriptional level, potentially involving indirect interactions with chromatin-associated regulatory systems. While direct DNA binding by Vilon has not been conclusively demonstrated, reported gene expression changes support continued investigation of transcriptional regulatory mechanisms in preclinical systems.
All available data regarding Vilon are derived exclusively from in vitro and animal studies. Vilon is not approved for human use, and no clinical trials have evaluated its safety, dosing, or biological effects in humans. Current research positions Vilon as an investigational compound used to study immune-related regulatory processes in experimental models.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, vilon has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Vilon research is most relevant to protocols examining:
Immune senescence and thymic gene expression research
Broad-spectrum longevity bioregulator protocol studies
Researchers studying the simplest Khavinson dipeptide bioregulator
Age-related immune decline investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Khavinson dipeptide (Lys-Glu) with broad regulatory activity; proposed to modulate immune senescence and gene expression in thymic and immune tissue, with reported longevity effects in rodent studies.
| Parameter | Value |
|---|---|
| Dose range | 10–20 mg/day (cycled) |
| Schedule | Daily (cycled) |
| Route | Subcutaneous |
| Half-life | ~Hours |
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.